DOCSLIB.ORG

LIGAND FORMULA INDEX CH5N 1 C3hlln3 68 CH603NP Z97 C3hll

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LIGAND FORMULA INDEX CH5N 1 C3HllN3 68 CH 0 NP Z97 6 3 C3Hll °3Nl 304 C3HIZ0gNP3 319 C H O N 164 Z 3 Z 3 C3HIZ0l0NP3 3Z0 CZH4OZN4 164 C H N 335 Z 5 C4H304N3 343 C H 0 N 347 Z 5 Z Z C4H4NZ 263,263,264 C H 0N Z6 Z 6 Z C4H402N2 34Z C H O N Z 6 Z 4 56 C4H403NZ 34Z C H N Z,72 2 7 C4H5ON Z 264 C H NS 3Z Z 7 C4H6NZ 146,148,149,349 C H 0N 15 Z 7 C4H6ON Z 15Z,15Z C H 0 NS 10 Z 7 3 C4H7N3 155 C H 0 NS 331 Z 7 4 C4H9N 7,73 C H N 36 2 8 Z C4HgN3 S2 348 C H 0 NP Z 8 3 Z98,246 C4HgON 81 C H 0 NP 3Z9 Z 8 4 C4HgON 2 348 C4HgOZN Z4,333,333 C H N 144,349 3 4 Z C4HgOZNS 33 C3H7N 6,331,335 C4H9OZN3 28,348 C H 0 N 23 3 7 2 C4Hg03 N 18 C3H80N 79 C4H904N2 77 Z7,3L,7 C3H80N2 C4H10NZ 91 3,331 C3HgN C4Hl00ZNZ 59 33,%7 C3H9NS C4H1006NP 346 347 C3HgN3 S C4HllN 3,5,7Z,331,331 C H ON 3 g 16,16,21 C4Hll NS 348 C H O N 347 3 g Z C4HllON 17,79,115,33Z,33Z,347 10 C3Hg03 NS C4HllONS 35 C H N 39,51,8Z 3 10 Z C4HllOZN 19,80 C H ON 57 3 10 Z C4Hl103N ZO 298,300,301 C3HIOO3 NP C4Hll03NS 11 393 394 LIGAND FORMULA INDEX C4H1ZN2 40,40,41,42,S2,S4,83,88,lZ0 CsHn 02N3 29,29 C4H12N2S 6S C5H12NZ 91,92,124 C4H12NZS2 66 CSH120NZ 14 C4H1ZON 2 S8,9S CSH1202NZ 334 C4H1Z03NP Z99,346 CSH13N 4,331,33S C4H13N3 69,101 CSH130N 17,337 C4H1306NPZ 318 CSH130ZN 117,336,347 C4H1404Nl2 Z93 CSH1303NS 11 C4H1406NZPZ 30S CSH14NZ S3,SS,84,84,92,337 CSH140N Z 96,97,348,348 CSH3N4Cl 344 CSH1403NP 317,346 CSH4NBr 340,340 CSH140SNP 317 CSH4NCI 340,340 CSHlSN3 103,103 CSH4N4 344 CSH16 N4 71 CSH4N4S 344 CSH1709Nl3 346 CSH40N4 34S CSH40ZN4 34S C6H4N2 177,177 CSHSN 16S C6H4ON4 3S3 CSHSNS 276 C6H402N4 3S3 CSHSNSS 344,344 C6HSON 191 340,340,340 CSHSON C6H6N4 339 CSHSONS 3S0 C6H60N2 184,196,197,198,340,340 CSHSONS 34S,3S3 C6H60N4 Z91,34S,34S CSHSOZN 179,3S0 C6~N 8,167,168,169 CSH6N2 20S,207,208 C6H7N2Cl 50 CSH6N6 34S C6H7 NS 344,344 CSH60N2 Z06 C6H70N 186,187,188,189,190,332 CSH602N2 271 C6H7ON3 192,193,194 CSH603N2 342,342 C6H703NS 12,13,331 CSH7NS 35 C6H704NS 332 219 CSH7 N3 C6H8N2 49,147,206,209 CSH70N Zl C6H803NZ 34Z CSH8NZ 148,lS0 C6H804NP 330 CSH8N2S 349 C6H9N 337 lS4,lS6,349,349 CSH9N3 C6H9N3 346 CSHl003NZ 30 C6H9OZN 333 5,73,337 CSHllN C6Hl0N2 150 C5HUON2 348 C6H10ON4 160 CSHl102N 333,333,333,336 C6HllN 335 C H 0 NS 334,334 S ll 2 C6HnN3 lS7,349 LIGAND FORMULA INDEX 395 H N 347 C6 UO C7H80N2 350 C6H110N3 158 C7H802N4 345 C6H12N2 48,48,126 C7H803N2 342 348 C6H12N4 C7H9N 7,9,9,170,171,171,172,172,173, C6H1203N2 30,31 174,331,340,340,347 348 C6H1203N4 C7H9NS 199,199 C H 0 N 114 6 12 4 C7H90N 22,22,331,340,340,340,350 H N 6,74,75,76,113,335 C6 13 C7H90N3 195,196 C6H1302N 333,333,333,333,348 C7H902N 341 C H 0 NS 6 13 2 334 C7H903NS 331,331 C H 0 N 6 13 2 3 333 C7H10N2 49,147,211,212,213,214 C6H14N2 45,46,87,121,336,336,336,338 C7H10ON 2 50,151,151 C H ON2 27,131,336,347 6 14 C7H1003 N2 342 + C6H1402N2 334 C7H11N2 220 C6H1402N4 60,63 C7H1102N3 159 C6H15 N 4,112,335,335 C7H1106NP 2 302 C6H15 N3 70,136,348 C7H13N2S 348 C H ON 1 6 15 116,3 +7 C7H13N3 158 C H 0 N 6 15 2 81,348 C7H13 ON 2 348,348 C H 0 N 6 15 3 ll8 C7H1304N 333 C6H1506N 347 C7H15N 76,113,335 C6H16 N2 43,85,89,121,125,334,347 C7H1502N 333,333,333,333,333 C6H16N2S2 67 C7H16N2 48,87,122 C6H16ON 2S 66 C7H16ON 2 28,336 C6H1602N2 58,98 C7H1602N2 334 C6H1606N2S2 34S C7H1602N4 61,64,348 C6H17 N3 104,132,133 C7H17 N 347 C6H18 N4 105,137 C7H17 ON 337,337 C6H2008 Nl4 296 C7H18N2 85,123 C6H20012Nl4 323 C7H19N3 132,133 C7H1909N2PS2 354 C7H50N3 353,353,353 C7H20N4 107 C7H502N2 350 163 C7H6N2 C8H6N2S 202,203,204 349 C7H7N3 C8H60N2 343,343,352,352,352,353,353, C7H70N 341,341,341 353 C H 0 N 341,341,341 7 7 2 CSH7 N3 161,162 C H 0 N lS5 7 7 2 3 CSHSN2 339 350,350 C7H704 N CSH8N4 352 C7H8N4 349 CSHSON 2 339 396 LIGAND FORMULA INDEX CSH902N 333,333,333,350 C9H5ONBr 2 351 CSH903N lSl C9H5ONC1 226 CSH904N 350 C9H50NI2 351 CSH10ON4 292,292 C9H6ONBr 351 CSH1006NP lS2 C9H6ONC1 351 CSH11N 340,340,347,350 C9H60NI 351 CSH110N lS,332,340,340,340,340 C9H603NBr 351 CSH110N2 350,350 C9H603NC1 351 CSH110N3 350 C9H603NI 351 CSH1102N 332 C9H603N2 351 CSH1103N lS0,332 C9H604NBrS 351 CS~103NP 346 C9H604NC1S 351 CSHl103NS 114 C9H604NIS 232,351 CSH1104NP 346 C9H606N2S 231 CgH12N2 43,215,216 C9H7N 222,222 CgH1202N2 lS3 C9~NS 200,200,201,201,202 CSH1203N2 342 C9H70N 223 + CSH13N2 220 C9H702N 351 CSH13N3 350,350,350 C9H702N3S 349 CSH1504N3 333 C9~04NS 227,351 CSH16ON 2 336 C9HSN2 234,339,339 CSH17N 75,337 C9HSON2 352,352 CSH17NS 34S C9H9N5 353 CSH1702N 333 C9H90N2 349 CSH1SON 2 7S,336 C9H10N2 339 CSH1S02N4 61 C9HlOON2 339 CSH1S04N2S 33S C9H1002N2 350 CSH1S06N2S2 34S C9H12N2 91 CSHl9 N 335,335,335 C9H1202N2 332 CSH190N 116 C9H1206N2 342 CSH1902N 34S C9H13N5 344 CSH1905N 337 C9H1303N 335,347 CSH20N2 90,122,336,33S C9H1305N3 265 CSH2002N2 99 C9H1309N2P 269 CSH2009N2S3 34S C9H14N2 34S CSH21N3 134 C9~40N2 216 CSH22N4 lOS C9H1407Nl 342 CgH2206Nl2 307 C9H14OSNl 265,266 CgHZ3 N5 111 C9H14012N2P2 269 C9HlSN 337 LIGAND FORMULA INDEX 397 + C9H1SN2 221 C10H1407NSP 278,279,280,345 C H1SN3 217 9 ClO\408NSP 344 C H O Nl2 267 9 1S ll C10H14 °Il NSP 2 289 270 C9H1S01SNl3 C10H1SN2 350 C9H16014Nl3 268 C10H1S ON 336,336 C H 0 N 9 17 4 333 C10H1S0N2 350 N 335 C9H19 C10H1S010Nl2 281 C H ON 78,336 9 20 2 C10H1S014N4P3 286,345 62 C9H2002N4 C10H1S014NSP3 290 C H 0 N 119 9 21 3 C10H16N6 160 109,138 C9H24N4 C10H1603N2 342 139 C9H2SNS C10H1601~NSP3 283 325 C9H2801SNls C10H17N2 221 C10H17013Nl3 273 235,341 C10H8N2 C10H17016NSP4 285 344 C10H8N10 C10H18N2 348 C H ONBr 351 10 8 C10H180SN4 333 C10H803N2 351 C10H19N 335 245 C10H9N3 C10H2004N6 348 C H ON 10 9 255,351,351,351 C10H2008N6 127 C H 0 NS 230 10 9 4 C10H22N2 86 332,347,347 C10H907NS2 C10H2202N2 348 C10H100N2 343 C10H2202N4 62 C H N 10 ll 3 351 C10H23N 335 142 C10H120N2 C10H24N2 338 342 C10H1203N2 C10H24N4 139 C10H120SN4 345 C10H2404N2 128 C10H1206N4 287,345 C10H2606Nl2S 314 C H 0 N 10 13 2 333 C10H2607Nl2 312 C H 0 N 332 10 13 3 C10H26012Nl4 354 344 C10H1303NS C10H2706Nl2 316 C10H1304NS 277 , 34~., 345 C10H28N6 140,348 C10H130SNS 345,353 345 C10H1308N4P CllH9N 175,175,176 C10H1308NSP 289 CllH90N 350 C10H1309N4 288 CllH902N3 178 C10H14N2 124 Cll H10N2 238 C10H1403N2 342 CnH1003N2 342 272 C10H1405NZ CllHn N4 244 C10H1406NSP 344 CllHllON 351 398 LIGAND FORMULA INDEX CllH120N2C12 274 C12H32N6 348 CllH13ON 2Cl 274 CllH1302N2 337,339 C13 Hl0N2 258,259 CllH1502N 333 C13H10ON3S 349 CllH1503N 25 C13Hl004N3S 349 CllH1603N2 342 C13HllON2 349 CllH17 N 337 C13 H130N3 349 CllH1703N 335,347 C13 H14N2 240 Cn H18N2 123 C13H14N4 218 CllH1803N2 342,342 Cl3H15ON5 353 CllH2402N4 348 C13H1504N5S 353 CllH26N2 338 C13H17 ON3 349 Cl1H 28 06Nl2 309 C13H3004N2 129 CllH30N6 141 C13H31N3 338 C12H6N2 352 C14H12N2 260,261,262 C12H7N2Br 256 C14H1402N2 350 C12H7N2Cl 254,255,352 C14H15N 335 C12H702N3 257 C14H16N2 241 C12H8N2 251 C14H18N4 248 C12H8ON 2 352 C14H1802N2 352 C12HllN 176 C14H2002N2 348 C12HllON 350 C14H2407N6 333 C12H12N2 239,341 C14H2802N2 100 C12H1202N2 352 C14H3002N4 94 C12H1203N2 343 C14H3204N2 l30 C12Hl3N3 236,341 C12H1402N2 143 C12H160N2 275 C15Hl1N3 352 C12H17 ON 347,347 C15H120N3 350,350 C12H1703N 333 C15H18N2 242 C12H18N2S2 348 C15H20N2 350 C12H1802N2 348 C12H1803N2 342 C16H16N2 341 C12H21N 337 C16H19N2Cl 350 C12H23N 335 C16H20N2 243,348 C12H24N2 44 C16H2002N2 93 C12H2402N2 348 C16H21N3 350 C12H2602N4 63,94 C16H22N4 no C12H29N3 135 C16H220N4 352 LIGAND FORMULA INDEX 399 C16H220 4Nl2 294 C19H21N5 250 C16H2206N2P2 295,310 C16H220SNl2 311 C20H14N4 352 C17H12N2 352 C21H2605N6 153 C17HlSN3 349 C17 H200 4 N6 353 C26H2SN6 249 C17 H21 ON 34S C32H1706N2 351 C1SH12N6 353 C32H2S010NSS2 349 ClSH1SN4 247 C1SH2604Nl2 327 C33H1906N2 351 ClSH2606Nl2 32S C1SH260SNl2 321 LIGAND NAME INDEX 2-Acetylpyridine, 341 Aminoacethydroxamic acid, 347 3-Acetylpyridine, 341 Aminobenzene, 8 4-Acetylpyridine, 341 2-Aminobenzenesulfonic acid, 331 2-Acetylpyridine oxime, 350 3-Aminobenzenesulfonic acid, 12 Adenine, 276 4-Aminobenzenesulfonic acid, 13 Adenine N(l)-oxide, 353 4-Aminobenzimidazole, 349 Adenosine, 277 4-Aminobenzoic acid 2-(diethylamino)ethyl ester, 348 Adenosine-2'-(dihydrogenphosphate), 278 2-Aminobenzoic acid methyl ester, 333 Adenosine-3'-(dihydrogenphosphate), 279 3-Aminobenzoic acid methyl ester, 333 Adenosine-5'-(dihydrogenphosphate), 280 .
Recommended publications
  • Réglementation De La Pharmacie

    Réglementation De La Pharmacie

    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
  • 29. Produits Chimiques Organiques

    29. Produits Chimiques Organiques

    29 Chapitre 29 Produits chimiques organiques Considérations générales Le Chapitre 29 ne comprend, en principe, que des composés de constitution chimique dé- finie présentés isolément, sous réserve toutefois des dispositions de la Note 1 du Chapitre. A) Composés de constitution chimique définie (Note 1 du Chapitre) Un composé de constitution chimique définie présenté isolément est une substance consti- tuée par une espèce moléculaire (covalente ou ionique, notamment) dont la composition est définie par un rapport constant entre ses éléments et qui peut être représentée par un diagramme structural unique. Dans un réseau cristallin, l'espèce moléculaire correspond au motif répétitif. Les composés de constitution chimique définie présentés isolément contenant des subs- tances qui ont été ajoutées délibérément pendant ou après leur fabrication (y compris la purification) sont exclus du présent Chapitre. Par conséquent, un produit constitué par exemple par de la saccharine mélangée avec du lactose afin qu'il puisse être utilisé comme édulcorant, est exclu du présent Chapitre (voir la Note explicative du no 2925). Ces composés peuvent contenir des impuretés (Note 1 a). Le libellé du no 2940 fait excep- tion à cette règle car, en ce qui concerne les sucres, il restreint la portée de la position aux sucres chimiquement purs. Le terme "impuretés" s'applique exclusivement aux substances dont la présence dans le composé chimique distinct résulte exclusivement et directement du procédé de fabrication (y compris la purification). Ces substances peuvent résulter de l'un quelconque des élé- ments intervenant au cours de la fabrication, et qui sont essentiellement les suivants: a) matières de départ non converties, b) impuretés se trouvant dans les matières de départ, c) réactifs utilisés dans le procédé de fabrication (y compris la purification), d) sous-produits.
  • 付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated

    付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated

    付表ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated Pharmaceutical Active Ingredients 号(Sub-heading) 品名 Description 2818.30 アルゲルドラート algeldrate 2833.22 アルスルフ alusulf 2842.10 アルマシラート almasilate 2842.10 シマルドラート simaldrate 2842.90 硫酸アルマドラ ート almadrate sulfate 2842.90 アルマガート almagate 2842.90 カルバルドラード carbaldrate 2842.90 ヒドロタルシト hydrotalcite 2842.90 マガルドラート magaldrate 2843.30 オーラノフィン auranofin 2843.30 金チオグリカニド aurothioglycanide 2843.30 金チオりんご酸ナトリウム sodium aurothiomalate 2843.30 金チオ硫酸ナトリウム sodium aurotiosulfate 2843.90 カルボプラチン carboplatin 2843.90 シスプラチン cisplatin 2843.90 デキソルマプラチン dexormaplatin 2843.90 エンロプラチン enloplatin 2843.90 イプロプラチン iproplatin 2843.90 ロバプラチン lobaplatin 2843.90 ミボプラチン miboplatin 2843.90 ネダプラチン nedaplatin 2843.90 オルマプラチン ormaplatin 2843.90 オキサリプラチン oxaliplatin 2843.90 セブリプラチン sebriplatin 2843.90 スピロプラチン spiroplatin 2843.90 ゼニプラチン zeniplatin 2844.40 アルツモマブ altumomab 2844.40 塩化セシウム(131Cs) cesium (131 Cs) chloride 2844.40 クロルメロドリン(197Hg) chlormerodrin (197 Hg) 2844.40 シアノコバラミン(57Co) cyanocobalamin (57 Co) 2844.40 シアノコバラミン(58Co) cyanocobalamin (58 Co) 2844.40 シアノコバラミン(60Co) cyanocobalamin (60 Co) 2844.40 エチオダイズド油(131I) ethiodized oil (131 I) 2844.40 くえん酸第二鉄(59Fe)注射液 ferric (59 Fe) citrate in 2844.40 フィブリノゲン(125I) fibrinogen (125 I) 2844.40 フルデオキシグルコー ス(18F) fludeoxyglucose ( 18 F) 2844.40 フルオロドパ(18F) fluorodopa (18 F) 2844.40 くえん酸ガリウム(67Ga) gallium (67 Ga) citrate 2844.40 金コロイド(198Au) gold (198 Au), colloidal 2844.40 イオベングアン(131I) iobenguane (131 I) 2844.40 よう化人血清アルブミン(125I) iodinated (125 I) human serum albumin 2844.40 よう化人血清アルブミン(131I) iodinated
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Identification of Four Novel Prognosis Biomarkers and Potential Therapeutic Drugs for Human Colorectal Cancer by Bioinformatics Analysis

    Identification of Four Novel Prognosis Biomarkers and Potential Therapeutic Drugs for Human Colorectal Cancer by Bioinformatics Analysis

    Available online at www.jbr-pub.org.cn Open Access at PubMed Central The Journal of Biomedical Research, 2021 35(1): 21–35 Original Article Identification of four novel prognosis biomarkers and potential therapeutic drugs for human colorectal cancer by bioinformatics analysis Zhen Sun1,2, Chen Liu1, Steven Y. Cheng1,3,✉ 1Department of Medical Genetics, 2Department of Pathology and Pathophysiology, 3Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Abstract Colorectal cancer (CRC) is one of the most deadly cancers in the world with few reliable biomarkers that have been selected into clinical guidelines for prognosis of CRC patients. In this study, mRNA microarray datasets GSE113513, GSE21510, GSE44076, and GSE32323 were obtained from the Gene Expression Omnibus (GEO) and analyzed with bioinformatics to identify hub genes in CRC development. Differentially expressed genes (DEGs) were analyzed using the GEO2R tool. Gene ontology (GO) and KEGG analyses were performed through the DAVID database. STRING database and Cytoscape software were used to construct a protein-protein interaction (PPI) network and identify key modules and hub genes. Survival analyses of the DEGs were performed on GEPIA database. The Connectivity Map database was used to screen potential drugs. A total of 865 DEGs were identified, including 374 upregulated and 491 downregulated genes. These DEGs were mainly associated with metabolic pathways, pathways in cancer, cell cycle and so on. The PPI network was identified with 863 nodes and 5817 edges. Survival analysis revealed that HMMR, PAICS, ETFDH, and SCG2 were significantly associated with overall survival of CRC patients.
  • Cardiac Ryr N-Terminal Region Biosensors for FRET-Based High-Throughput Screening

    Cardiac Ryr N-Terminal Region Biosensors for FRET-Based High-Throughput Screening

    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.07.430153; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cardiac RyR N-terminal region biosensors for FRET-based high-throughput screening Jingyan Zhang1, Siobhan M. Wong King Yuen,2 Jacob A. Schwarz1, Levy M. Treinen1, Ching-Chieh Tung2, Robyn T. Rebbeck1, Kaja Berg3, Bengt Svensson1, Courtney C. Aldrich3, David D. Thomas1, Filip Van Petegem2, and Razvan L. Cornea1* 1Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA. 2Department of Biochemistry and Molecular Biology, Life Sciences Institute, University of British Columbia,V6T 1Z3 Vancouver, BC, Canada. 3Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, 55455, USA. Corresponding author: Razvan L. Cornea Email: [email protected] Running title: FRET biosensor constructs for RyR-targeted drug discovery Keywords: Ryanodine receptor; N-terminal region; FRET; fluorescence lifetime; high-throughput screening; myopathy. bioRxiv preprint doi: https://doi.org/10.1101/2021.02.07.430153; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract failure (HF) (9-13). Physiologically, the opening and closing of RyR channels are tightly regulated The N-terminal region (NTR) of the ryanodine by small molecules, ions, and proteins(14), many receptor (RyR) calcium channels is critical to the of them binding to the enormous RyR cytoplasmic 2+ regulation of Ca release during excitation- portion, with functional effects allosterically contraction coupling.
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • I (Acts Whose Publication Is Obligatory) COMMISSION

    I (Acts Whose Publication Is Obligatory) COMMISSION

    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
  • The Inhibition of Noradrenaline Uptake by Sympathomimetic Amines in the Rat Isolated Heart

    The Inhibition of Noradrenaline Uptake by Sympathomimetic Amines in the Rat Isolated Heart

    Brit. J. Pharmacol. (1965), 25. 34-49. THE INHIBITION OF NORADRENALINE UPTAKE BY SYMPATHOMIMETIC AMINES IN THE RAT ISOLATED HEART BY A. S. V. BURGEN AND L. L. IVERSEN From the Department ofPharmacology, University of Cambridge (Received August 30, 1964) -In the rat isolated heart, noradrenaline can be accumulated by two distinct processes. The first process (Uptake1) is half saturated at a (±)-noradrenaline concentration of 0.11 pg/ml. and continues to operate at external noradrenaline concentrations up to 1 ,ug/ml. (Iversen, 1963). The second process comes into play at slightly higher concentra- tions and becomes half saturated at 42.6 ,ug/ml. (Iversen, 1965b). Both of these processes act also upon adrenaline, which competes for uptake when noradrenaline is also present (Iversen, 1965a, b). It seems probable, therefore, that other sympathomimetic amines would have an affinity for the systems operative in accumulation, and indeed, there is some evidence in the literature that amphetamine, tyramine and ephedrine inhibit noradrenaline uptake (Dengler, Spiegel & Titus, 1961; Axelrod & Tomchick, 1960). This paper is concerned with the measurement of the affinity of sympathomimetic amines for the uptake system as measured by inhibition of noradrenaline accumulation. Needless to say, the demonstration that a substance inhibits noradrenaline uptake does not prove that it is also transported by the system; this would require a direct measurement of the accumulation of the substance in the tissue. A preliminary account of some of these results has already been published (Iversen, 1964). METHODS Inhibition of UptakeL In control experiments, hearts were perfused with a medium containing (±)-[_4C]noradrenaline (Nichem Inc., Bethesda, Maryland, U.S.A.) at a concentration of 10 ng/ml.
  • Council of Europe Committee of Ministers (Partial

    Council of Europe Committee of Ministers (Partial

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0043408A1 Yeboah Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2005/0043408A1 Yeboah Et Al

    US 2005.0043408A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0043408A1 Yeboah et al. (43) Pub. Date: Feb. 24, 2005 (54) ANTI-GLYCATION AGENTS FOR Related U.S. Application Data PREVENTINGAGE- DIABETES- AND SMOKING-RELATED COMPLICATIONS (60) Provisional application No. 60/328,808, filed on Oct. 15, 2001. (76) Inventors: Faustinus Yeboah, Longueuil (CH); Publication Classification Yasuo Konishi, Kirkland (CA); Sung Ju Cho, Montreal (CA); Jittiwud (51) Int. Cl." ...................... A61K 31/195; CO7C 31/137 Lertvorachon, Montreal (CA); Taira (52) U.S. Cl. ........................... 514/567; 514/649; 514/651 Kiyota, St. Laurent (CA); Popek Tomasz, Pointe-Claire (CA) (57) ABSTRACT The invention provides new inhibitors of protein glycation, Correspondence Address: identified from compound libraries by a high throughput BORDEN LADNER GERVAS LLP Screening assay. The anti-glycation agents So identified are WORLD EXCHANGE PLAZA characterized by a variety of chemical Structures and are 100 QUEEN STREETSUITE 1100 useful for the prevention or treatment of age-, diabetes-, and OTTAWA, ON K1P 1J9 (CA) Smoking-related complications, including neuropathy, neph ropathy, ocular pathologies, or the loSS of mechanical prop erties of collagenous tissues. Among compounds identified (21) Appl. No.: 10/492,553 as having the anti-glycation activity, of Special interest are epinephrine and its analogs, in particular D-epinephrine and (22) PCT Filed: Oct. 15, 2002 its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and Smoking-related ocular (86) PCT No.: PCT/CA02/01552 pathologies. Patent Application Publication Feb. 24, 2005 Sheet 1 of 2 US 2005/0043408 A1 100 L-Norepinephrine IC50=59 uM 8 O 60 | 4.O 2 O Log inhibitor FIG.
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7